AMF Medical’s Sigi Wearable Insulin Management System Receives FDA Breakthrough Device Designation

AMF Medical announced that its Sigi™ Insulin Management System, for diabetes treatment, has been ...

Image: AMF Medical

AMF Medical announced that its Sigi™ Insulin Management System, for diabetes treatment, has been granted Breakthrough Device Designation by the US Food and Drug Administration. Sigi is the only insulin patch pump for closed loop integration designed for use with standard, pre-filled pump cartridges.

Read more: Scientists Develop Ingestible Robot That Delivers Insulin Without The Need For External Needles

Sigi can be programmed to deliver basal and bolus insulin at both set and variable rates. In addition, as an Alternate Controller Enabled-pump, it is able to receive, execute and confirm dosing commands by interacting with Bluetooth-compatible, continuous glucose monitors and alternate controller devices, like a smartphone or an iController, the company said in a press release.

Sigi is also smaller, lighter, and more convenient than current insulin delivery systems. This is made possible by its ergonomic design, which accommodates standard, insulin pre-filled pump cartridges.

AMF Medical Co-CEO and Co-Founder Mr. Antoine Barraud said: “We would like to thank the FDA for recognizing our team's proprietary, patient-focused technology, which provides users with enhanced clinical and convenience features. This Breakthrough Device Designation will expedite the development of Sigi and prioritize its review in future FDA regulatory submissions. It is a huge step forward in bringing Sigi to market to improve insulin management.”

“Clinical study data has shown that Sigi is delightfully easy to use. Study patients have expressed satisfaction as well as eagerness for this next-generation patch to be readily available. We are pleased that the FDA also sees its clear value and is moving the process forward,” said Professor A. Wojtusciszyn, MD, Ph.D. from Lausanne University Hospital (CHUV) and principal investigator of the first Sigi clinical study.

Read more: Medtronic Launches Smart Insulin Pen with Real-Time CGM Data For People on Multiple Daily Injections

About AMF Medical

Originally founded in 2014 in the Swiss Medtech Valley, AMF Medical is developing a novel technology to address the unmet needs of people on insulin therapy. The company's flagship product, Sigi, is a next-generation, plug 'n go, semi-reusable, and rechargeable patch pump, designed to make life easier for people with diabetes. Sigi is intended for prescription use only and is not yet FDA Cleared nor CE-marked. AMF Medical is led by Co-CEOs Mr. Pim van Wesel and Mr. Antoine Barraud, Ph.D. who is also a Co-Founder. Diabetes industry experts John Timberlake and Peter Gerhardsson serve on the company's Board of Directors.

Sam Draper
December 7, 2021

Innovation of the Month

Do you want to discover more, visit the website
Visit Website

Other news

Senseonics Gets FDA Approval for Eversense Implantable CGM System

Senseonics CGM system received FDA approval.

Fitbit OS Update Improves Heart Rate Tracking, Sleep Tools, On-Device Watch Face Adjustments

Fitbit has updated its Fitbit OS operating system for its popular smartwatches...

Raspberry Pi Launches $4 Microcontroller Running on a Custom Processor

Raspberry Pi has launched its first microcontroller, Raspberry Pi Pico. The $4 microcontroller is...

Fighting Against NCDs - Wearables for Chronic Disease Management and Mobility Challenges

Noncommunicable diseases (NCDs) constitute one of the major public health challenges for development
Discover more